Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18557032 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL30542346 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL30542347 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL15443235 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL18760457 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL12326212 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL18552 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL1818944 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL29058069 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL6966832 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3406608-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | LES LABORATOIRES SERVIER SAS (FR) | 2021-09-15 | — | — | EP | disclosed |
| US-9512107-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | DIXON BRIAN R (US) | 2003-11-06 | — | — | US | disclosed |
| US-6353006-B1 | TREATMENT OF BONE DISORDERS, OSTEOPOROSIS AND HEALING AGENT | BAYER CORPORATION | 2002-03-05 | — | — | US | disclosed |
| CN-1337955-A | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents | AMERICAN BAYER CORP (US) | 2002-02-27 | — | — | CN | disclosed |
| US-3932484-A | FROM CYCLODODECATRIENE AND CARBON MONOXIDE, COORDINATION CATALYST | TEXACO INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | PGR, PGRMC2, PGRMC1 | SMN1; SMN2 4733/4885POLB 4005/4885ALDH1A1 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.